Efficacy of Topotecan in Pretreated Metastatic Neuroendocrine Carcinoma

#1095

Introduction: Therapeutic options for metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC) after prior platinum-based chemotherapy are limited. Topotecan is an approved second line chemotherapy for small cell lung cancer (SCLC) which is often considered to show a biological behavior similar to NEC.

Aim(s): To analyze the efficacy of topotecan in pretreated metastatic NEC patients.

Materials and methods: We performed an updated retrospective analysis of all patients treated with topotecan for metastatic NEC who presented at our center between January 2005 and December 2013.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Apostolidis L

Authors: Apostolidis L, Jäger D, Winkler E,

Keywords: neuroendocrine carcinoma, chemotherapy, topotecan,

To read the full abstract, please log into your ENETS Member account.